 |
|
Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines
Nicole L. Glazer, MPH;
Sascha Dublin, MD, PhD;
Nicholas L. Smith, PhD, MPH;
Benjamin French, MS;
Lisa A. Jackson, MD, MPH;
Jennifer B. Hrachovec, PharmD;
David S. Siscovick, MD, MPH;
Bruce M. Psaty, MD, PhD;
Susan R. Heckbert, MD, PhD
Arch Intern Med. 2007;167(3):246-252.
Background Guidelines recommend the use of antithrombotic therapy for stroke prevention in patients with atrial fibrillation (AF), but compliance with such guidelines has not been widely studied among patients with newly detected AF. Our objective was to assess compliance with antithrombotic guidelines and to identify patient characteristics associated with warfarin use.
Methods A population-based study of newly detected AF (patient age, 30-84 years) was conducted within a large health plan. Cardiovascular disease risk factors, comorbid conditions, medication use, and international normalized ratios were abstracted from the medical record. Patients were stratified by embolic risk according to American College of Chest Physicians (ACCP) criteria. We analyzed the proportion of patients with AF receiving warfarin or aspirin ( 325 mg/d) during the 6 months following AF. Relative risk regression estimated the association of risk factors and patient characteristics with warfarin use.
Results Overall, 73% of patients (418/572) with newly detected AF had evidence of antithrombotic use after AF onset. Among the 76% (437/572) of patients with AF at high risk for stroke, 59% (257/437) used warfarin, 28% (123/437) used aspirin, and 24% (104/437) used neither. The major predictor of warfarin use was AF classification; intermittent or sustained AF had relative risks for warfarin use of 2.8 (95% confidence interval, 2.2-3.6) and 2.9 (95% confidence interval, 2.2-3.7), respectively, compared with transitory AF.
Conclusions Three quarters of the patients with newly detected AF received antithrombotic therapy, yet many at high risk of stroke did not receive warfarin. Atrial fibrillation classification, rather than stroke risk factors, was strongly associated with warfarin use.
Author Affiliations: Cardiovascular Health Research Unit and Department of Epidemiology (Ms Glazer and Drs Smith, Siscovick, Psaty, and Heckbert), and Departments of Biostatistics (Mr French), Medicine (Drs Siscovick and Psaty), and Health Services (Dr Psaty), University of Washington, VA Puget Sound Health Care System (Dr Dublin), and Center for Health Studies, Group Health Cooperative (Drs Jackson, Hrachovec, and Heckbert), Seattle.
RELATED ARTICLES
The Influence of Patient Adherence on Anticoagulation Control With Warfarin: Results From the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study
Stephen E. Kimmel, Zhen Chen, Maureen Price, Catherine S. Parker, Joshua P. Metlay, Jason D. Christie, Colleen M. Brensinger, Craig W. Newcomb, Frederick F. Samaha, and Robert Gross
Arch Intern Med. 2007;167(3):229-235.
ABSTRACT
| FULL TEXT
Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control: Results From SPORTIF III and V
Harvey D. White, Michael Gruber, Jan Feyzi, Scott Kaatz, Hung-Fat Tse, Steen Husted, and Gregory W. Albers
Arch Intern Med. 2007;167(3):239-245.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert et al.
Arch Intern Med 2008;168:826-831.
ABSTRACT
| FULL TEXT
New oral anticoagulants in atrial fibrillation
Turpie
Eur Heart J 2008;29:155-165.
ABSTRACT
| FULL TEXT
The Year in Epidemiology, Health Services Research, and Outcomes Research
Krumholz and Masoudi
J Am Coll Cardiol 2007;50:2254-2262.
FULL TEXT
Warfarin Therapy in Clinical Practice
JWatch Neurology 2007;2007:2-2.
FULL TEXT
Antithrombotic Therapy for Atrial Fibrillation
JWatch Oncology and Hematology 2007;2007:1-1.
FULL TEXT
|
